- Home
- VERB vs BDRX Comparison
VERB vs BDRX Comparison
Compare VERB & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERB
- BDRX
- Stock Information
- Founded
- VERB 2014
- BDRX 2000
- Country
- VERB United States
- BDRX United Kingdom
- Employees
- VERB N/A
- BDRX 13
- Industry
- VERB Other Consumer Services
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- VERB Consumer Discretionary
- BDRX Health Care
- Exchange
- VERB Nasdaq
- BDRX Nasdaq
- Market Cap
- VERB 4.1M
- BDRX 3.5M
- IPO Year
- VERB N/A
- BDRX N/A
- Fundamental
- Price
- VERB $4.82
- BDRX $1.55
- Analyst Decision
- VERB Strong Buy
- BDRX
- Analyst Count
- VERB 1
- BDRX 0
- Target Price
- VERB $60.00
- BDRX N/A
- AVG Volume (30 Days)
- VERB 55.1K
- BDRX 1.2M
- Earning Date
- VERB 05-09-2025
- BDRX 05-02-2025
- Dividend Yield
- VERB N/A
- BDRX N/A
- EPS Growth
- VERB N/A
- BDRX N/A
- EPS
- VERB N/A
- BDRX N/A
- Revenue
- VERB $895,000.00
- BDRX N/A
- Revenue This Year
- VERB $36.76
- BDRX N/A
- Revenue Next Year
- VERB N/A
- BDRX N/A
- P/E Ratio
- VERB N/A
- BDRX N/A
- Revenue Growth
- VERB 1320.63
- BDRX N/A
- 52 Week Low
- VERB $3.81
- BDRX $1.14
- 52 Week High
- VERB $40.40
- BDRX $74.00
- Technical
- Relative Strength Index (RSI)
- VERB 53.45
- BDRX 43.94
- Support Level
- VERB $3.82
- BDRX $1.24
- Resistance Level
- VERB $4.78
- BDRX $1.52
- Average True Range (ATR)
- VERB 0.44
- BDRX 0.20
- MACD
- VERB 0.07
- BDRX 0.07
- Stochastic Oscillator
- VERB 87.29
- BDRX 49.21
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.